| Autor: |
David A. Largaespada, Aaron L. Sarver, Michael D. Taylor, Annie Huang, David J. Odde, Robert J. Wechsler-Reya, Robert B. Jenkins, Charles G. Eberhart, Stephen C. Schmechel, Anthony E. Rizzardi, Michelle M. Frees, Addison M. Demer, Amy M. Molan, Ryan D. Krebs, Quincy Rosemarie, Fausto J. Rodriguez, Xiaochong Wu, Daniel Picard, Branden S. Moriarity, Adrian M. Dubuc, Paramita Das, Barbara R. Tschida, Catherine Lee, Jun Wang, Rory L. Williams, George M. Otto, Ghaidan A. Shamsan, Eric P. Rahrmann, Sandra Wagner, Jason P. Ostergaard, Alex T. Larsson, Jon D. Larson, Pauline J. Beckmann |
| Rok vydání: |
2023 |
| Popis: |
Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNET) are aggressive, poorly differentiated brain tumors with limited effective therapies. Using Sleeping Beauty (SB) transposon mutagenesis, we identified novel genetic drivers of medulloblastoma and CNS-PNET. Cross-species gene expression analyses classified SB-driven tumors into distinct medulloblastoma and CNS-PNET subgroups, indicating they resemble human Sonic hedgehog and group 3 and 4 medulloblastoma and CNS neuroblastoma with FOXR2 activation. This represents the first genetically induced mouse model of CNS-PNET and a rare model of group 3 and 4 medulloblastoma. We identified several putative proto-oncogenes including Arhgap36, Megf10, and Foxr2. Genetic manipulation of these genes demonstrated a robust impact on tumorigenesis in vitro and in vivo. We also determined that FOXR2 interacts with N-MYC, increases C-MYC protein stability, and activates FAK/SRC signaling. Altogether, our study identified several promising therapeutic targets in medulloblastoma and CNS-PNET.Significance:A transposon-induced mouse model identifies several novel genetic drivers and potential therapeutic targets in medulloblastoma and CNS-PNET. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
